It doesn't matter what banner is on the door, VC, PE, HF, it is capital that is needed and massive overhaul of management.
Yes, capital would be awesome (dilutive but awesome) but if it is just another Allianz, the company hasn't progressed, because the management is still the same, doing the same old nonsense.
A healthcare dedicated anything (VE, PE etc) would be a powerful sign, as they carry contacts and know-how to steer a ship like this, but if it is just another regular old 51Cap or standard Fund Manager, nothing changes (outside of massive dilution to secure funding $'s).
Royalties - I have outlined this previously, there is no-one who will stump up $50m now, for a cut of future royalties and that "cut" of future royalties is simply your dilution of profits, distributable to you the shareholder (dilution with a mask...)
If the company hasn't been able to attract a dedicated healthcare fund by now, I see nothing in recent announcements that would get them off of the fence.
I laid out the basic due diligence in an earlier thread, but please ask yourself if you would loan money to this company, when they cannot articulate how much money they need.
- Forums
- ASX - By Stock
- PAR
- How would involvement from a Venture capitalists or Private equity group look for Paradigm
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
2.20%
!
46.5¢

How would involvement from a Venture capitalists or Private equity group look for Paradigm, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
46.5¢ |
Change
0.010(2.20%) |
Mkt cap ! $184.8M |
Open | High | Low | Value | Volume |
45.5¢ | 48.0¢ | 44.0¢ | $534.2K | 1.168M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5245 | 45.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
47.0¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5245 | 0.455 |
1 | 23000 | 0.450 |
1 | 15000 | 0.445 |
1 | 10000 | 0.440 |
1 | 17857 | 0.435 |
Price($) | Vol. | No. |
---|---|---|
0.470 | 10000 | 1 |
0.475 | 13560 | 2 |
0.480 | 110598 | 4 |
0.485 | 10000 | 1 |
0.490 | 18000 | 2 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online